1921.4000 -14.10 (-0.73%)
NSE Jul 13, 2026 15:31 PM
Volume: 1.6M
 

1921.40
-0.73%
Emkay
Sun’s 2QFY26 EBITDA was ahead of the street and our estimates (by ~12%), on the back of a marginally higher gross margin and lower R&D spend.
Number of FII/FPI investors increased from 1229 to 1246 in Mar 2026 qtr.
More from Sun Pharmaceutical Industries Ltd.
Recommended